Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 10/20 | 0.47 |
| ▸ | CTSS | P25774 | 7/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18341271 | 1.00 | SYK (0.50) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL30489643 | 1.00 | SYK (0.50) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL24257009 | 0.93 | SYK (0.48) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL13055405 | 0.91 | SYK (0.54) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5544757 | 0.90 | CTSS (0.47) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL20974393 | 0.90 | SYK (0.48) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL8782362 | 0.88 | CTSK (0.42) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL5025247 | 0.87 | SYK (0.43) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2861782 | 0.87 | CA1 (0.52) | CTSKCTSSCTSLCTSBTDP1 | |
| SCHEMBL24257159 | 0.86 | SYK (0.49) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021115444-A1 | MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2020037652-A1 | HUMAN TOPOISOMERASE II-TARGETING ORGANOPLATINUM COMPOUNDS | LI TSAI KUN (CN) | 2020-02-27 | — | — | WO | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-0629617-B2 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 2007-09-26 | — | — | EP | disclosed |
| US-20040005274-A1 | Targeting multimeric imaging agents through multilocus binding | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6652835-B1 | Improved relaxivity properties upon binding | EPIX MEDICAL, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-0629617-B1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INT BV (NL) | 1998-04-29 | — | — | EP | disclosed |
| US-5665329-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-09-09 | — | — | US | disclosed |
| US-5656254-A | Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy | BRACCO INTERNATIONAL B.V. | 1997-08-12 | — | — | US | disclosed |
| US-5627286-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-05-06 | — | — | US | disclosed |
| US-5608110-A | Heteroatom-bearing ligands and metal complexes thereof | BRACCO INTERNATIONAL B.V. | 1997-03-04 | — | — | US | disclosed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | disclosed |
| EP-0144825-B1 | CYCLIC GUANIDINYL THIO CARBAPENEMS | MERCK & CO. INC. (US) | 1989-07-05 | — | — | EP | disclosed |
| US-4717728-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1988-01-05 | — | — | US | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | disclosed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | SYK 680/4885CTSK 584/4885CTSS 304/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | SYK 683/4885CTSK 624/4885CTSS 314/4885 |
| US-20040005274-A1 | Targeting multimeric imaging agents through multilocus binding | ILK, PBRM1, FABP1 | SYK 2284/4885CTSK 3535/4885CTSS 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.